Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Patients with non-small-cell lung cancer harboring susceptibility mutations in the epidermal growth factor receptor (EGFR) did better with gefitinib given as first-line therapy…
NEW YORK (Reuters Health) – Breast cancer patients found to have micrometastases in the sentinel lymph node (SLN) but who do not undergo completion axillary lymph node dissection…
NEW YORK (Reuters Health) – In the treatment of nodular goiter, the effect of radioiodine (I-131) therapy is potentiated by neoadjuvant administration of recombinant human thyroid stimulating hormone…
NEW YORK (Reuters Health) – For locally advanced and metastatic prostate cancer, the best timing and duration of androgen-deprivation therapy (ADT) is unclear. Now, a systematic review suggests…
NEW YORK (Reuters Health) – In selected patients with upper tract urothelial carcinoma, endoscopic management offers a nephron-sparing alternative to nephroureterectomy, researchers report in the June issue of…
NEW YORK (Reuters Health) – Misoprostol plus oxytocin is no more effective than oxytocin alone for controlling atonic post-partum hemorrhage, but it has more side effects, according to…
NEW YORK (Reuters Health) – For distinguishing epithelial ovarian cancer from a benign mass, an algorithm that uses HE4 and CA125 is more sensitive and objective than the…
Actinic Keratoses (AKs) are precancerous growths on the skin, typically characterized by rough and dry skin lesions. In this video, Gary Goldenberg, MD, Assistant Professor of Dermatology and…
Protein energy malnutrition can cause death in post-operative and cancer patients. New protein-rich snacks can help remedy that situation, and offer a new solution for cancer patients undergoing…
NEW YORK (Reuters Health) – Mounting evidence suggests that preoperative prostate specific antigen (PSA) kinetics are a poor marker of disease progression. During active surveillance for low-risk, low-volume…
